Alzheimer’s disease, neuromuscular and neurological disorders, mental health therapeutics: approvals, coverage and access.
Cristália’s Phase 1 safety trial of polilaminina for acute spinal cord trauma was scheduled to begin 24 September 2026 after authorisation from Brazil’s health regulator, Anvisa, in January — with …
Anvisa cancelled Elevidys’s conditional registration on August 24 at Roche’s request, citing insufficient safety and efficacy data — ending Brazilian access to the country’s most expensive approved drug.
Medtronic’s $650M bid for SPR Therapeutics brings the FDA-cleared SPRINT Peripheral Nerve Stimulation System into its portfolio, offering a 60-day, non-permanent pain therapy backed by 6,100-patient real-world data showing 71% …
Biogen reports $2.5B Q1 revenue, +2% YoY, with non-GAAP EPS of $3.57, up 18%. LEQEMBI’s 78% 18-month persistence rate and a new high-dose SPINRAZA FDA approval signal commercial and pipeline …
Mendoza becomes the first Argentine province to screen newborns for spinal muscular atrophy at birth, enabling pre-symptomatic treatment under a public-private accord with Novartis effective May 24, 2026.
You must be logged in to post a comment.